FDA approved Truqap (capivasertib) with fulvestrant for adult patients with hormone receptor-positive, human epidermal growth factor receptor-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
FDA has granted approval for the HistoSonics’ Edison histotripsy device to treat liver tumors.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending approval of Keytruda (pembrolizumab) in combination with gemcitabine and cisplatin, for the first-line treatment of adult patients with locally advanced unresectable or metastatic biliary tract carcinoma.
Legend Biotech Ireland Limited, a wholly owned subsidiary of Legend Biotech, has entered into an exclusive, global license agreement with Novartis Pharma AG for certain Legend Biotech chimeric antigen receptor T-cell therapies targeting DLL3, including its autologous CAR-T cell therapy candidate, LB2102 (NCT05680922).
Monica M. Bertagnolli, the 16th NCI director, has been confirmed as the 17th director of NIH—six months after the White House first named her to lead the world’s largest public funder of biomedical research.
Today’s traditional research model relies on incremental innovation that builds upon the shoulders of other researchers’ work, making small but steady strides. Occasionally, leaps are made by researchers who develop new classes of therapy such as stem cell transplant or CAR-T immunotherapy. But cancer patients may not have the luxury to wait 20 years for the traditional scientific process to evolve for their cancer. They can’t wait for a cure.
MD Anderson Cancer Center launched its Institute for Data Science in Oncology, or IDSO, which integrates the most advanced computational and data science approaches with the institution’s extensive scientific and clinical expertise to significantly improve patient’s lives by transforming cancer care and research.
Alan H. Bryce was named chief clinical officer at City of Hope Cancer Center Phoenix and professor of molecular medicine at Translational Genomics Research Institute (TGen), part of City of Hope.
Craig D. Blinderman was named chief of the Supportive Care Service at Memorial Sloan Kettering Cancer Center.
Agnes Hsu, a clinical nurse, has received the 2023 Brown Foundation Award for Excellence in Oncology Nursing from MD Anderson Cancer Center.
